[vc_row][vc_column][vc_single_image image=”24691″ img_size=”full”][vc_column_text]
The Next Hot Biotech Stock… Can It Beat The Biotech Index?
Biogen (Nasdaq: BIIB) rose as much as 300% in the last five years and if you were in on it, you did well. But this biotech stock could show that kind of results in just a matter of a few months…. You’ve probably read about the massive gains already in this sector and unless you’re brain dead, you’ll want to know about the next hot biotech stock.
Investors have been climbing on board and the stock has been going nowhere but up…
The Washington Post says, “this industry could be bigger than the NFL by 2020.” And in case you’re wondering that’s $35 BILLION compared to $10 BILLION for the NFL.
Are your juices flowing yet? They should be. HERE’S WHY…
While there’s oodles of cash driving this industry this biotech stock is one that is going to bolt!
In the last month the SPDR S&P Biotech ETF (XBI) is off more-than 5% – while Vitality Biopharma [stock symbol=”VBIO”] HAS NEARLY DOUBLED IN PRICE.
We’re featuring one of the hottest biotech stocks out there that’s grabbing investors’ attention, Vitality Biopharma and for no small reason. Read on…
Vitality Biopharma is developing proprietary treatment protocols of serious neurological and inflammatory disorders, such as inflammatory bowel disease and multiple sclerosis.
Vitality Biopharma [stock symbol=”VBIO”] has developed a new class of treatment protocols.
WANT TO KNOW MORE?
Don’t be brain dead… this is NOT some blue sky pitch and clinical trials support that.
Inflammatory Bowel Disease
Muscle spasticity (in Multiple Sclerosis)
That enough proof? Now you know why biotech stock lovers are putting shares of Vitality Biopharma [stock symbol=”VBIO”] in their portfolio of Biotech Stocks – and you should too!!
CHECK OUT THEIR NEWS! It’s nothing but PROGRESS, PROGRESS, PROGRESS>
The next hot biopharma stock is here!!!
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of financialstrend.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: